Technical Analysis for REPL - Replimune Group, Inc.

Grade Last Price % Change Price Change
grade B 14.07 4.77% 0.64
REPL closed up 4.77 percent on Friday, February 15, 2019, on 1.89 times normal volume. It was able to find support at its 50 day moving average.
0 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong N/A Up Up
See historical REPL trend table...

Date Alert Name Type % Chg
Feb 15 20 DMA Support Bullish 0.00%
Feb 15 50 DMA Support Bullish 0.00%
Feb 15 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Feb 15 Pocket Pivot Bullish Swing Setup 0.00%
Feb 15 Wide Range Bar Range Expansion 0.00%
Feb 15 Upper Bollinger Band Walk Strength 0.00%
Feb 15 Outside Day Range Expansion 0.00%
Feb 15 Wide Bands Range Expansion 0.00%
Feb 15 Upper Bollinger Band Touch Strength 0.00%
Feb 14 50 DMA Support Bullish 4.77%

Older signals for REPL ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Analyze My Stocks!
Configure default chart indicators
Basic chart:

Profile
  • Earnings date: 2019-02-13
Replimune Group, Inc. is a clinical-stage biotechnology company. The Company is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The Company applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The Company is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP, RP2, and RP3. The Company is focused on Phase 1/2 clinical trial with its lead product candidate, RP1, in approximately 150 patients with a range of solid tumors.
Medicine Biotechnology Cancer Clinical Medicine Solid Tumors Immunotherapy Cancer Treatments Virotherapy Experimental Cancer Treatments Transgene Sa
Is REPL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Feb 11 Microcaps dominate midday movers
Feb 11 NuVasive and OHR Pharmaceutical among healthcare gainers; Celldex Therapeutics leads the losers
Feb 7 Replimune to Present at Two Upcoming Investor Conferences
Jan 10 Replimune Group (REPL) Presents At 37th Annual J.P. Morgan Healthcare Conference - Slideshow
Jan 3 Replimune Highlights Company Progress and Expected 2019 Milestones Ahead of Presentation at the 37th Annual JPMorgan Healthcare Conference
Dec 28 Healthcare & Tech dominate midday movers
Dec 28 OPKO Health and Prana Biotechnology among healthcare gainers; Novus Therapeutics among losers
Dec 27 Microcaps mostly among midday movers
Dec 20 Replimune to Present at the 37th Annual J.P.Morgan Healthcare Conference
Dec 12 Replimune (REPL) Presents At BMO 2018 Prescriptions for Success Healthcare Conference - Slideshow
See more REPL news...
Indicators
Indicator Value
52 Week High 23.55
52 Week Low 8.88
Average Volume 47,799
200-Day Moving Average 0.0
50-Day Moving Average 12.4174
20-Day Moving Average 12.4495
10-Day Moving Average 13.819
Average True Range 1.5909
ADX 30.0
+DI 25.779
-DI 15.2221
Chandelier Exit (Long, 3 ATRs ) 12.2373
Chandelier Exit (Short, 3 ATRs ) 14.8727
Upper Bollinger Band 15.7307
Lower Bollinger Band 9.1683
Percent B (%b) 0.75
BandWidth 52.712157
MACD Line 0.7276
MACD Signal Line 0.4856
MACD Histogram 0.242
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.68
Resistance 3 (R3) 19.63 17.72 18.75
Resistance 2 (R2) 17.72 16.29 17.74 18.43
Resistance 1 (R1) 15.89 15.41 16.81 15.94 18.12
Pivot Point 13.98 13.98 14.43 14.00 13.98
Support 1 (S1) 12.15 12.55 13.07 12.20 10.02
Support 2 (S2) 10.24 11.67 10.26 9.71
Support 3 (S3) 8.41 10.24 9.40
Support 4 (S4) 8.46